Clorox now has a clearly scheduled earnings catalyst. The company said it will issue fourth-quarter and fiscal-year 2026 results on Monday, August 3, 2026, with the press release and prepared remarks due at 4:15 p.m. Eastern Time and the live Q&A webcast set for 5:00 p.m. Eastern Time. For options traders, that matters because CLX is not heading into this report as a generic defensive stock. It is heading into the event after a quarter with flat sales, lower full-year earnings guidance, and a management explanation that a large share of the pressure comes from ERP-related inventory timing rather than a clean read on end demand.
That is what makes this an options setup instead of just another calendar entry. Clorox’s own recent releases show a company trying to separate temporary operational unwind from the deeper question traders actually care about: whether category volume, margins, and execution are stabilizing fast enough to justify a calmer post-earnings reaction. Into August 3, the practical question is not whether Clorox still owns recognizable brands. The question is whether the company can convince the market that fiscal 2026 is the trough of an ERP-disrupted reset rather than evidence of a longer, lower-growth staples story.
This article is market commentary and options education only. It is not financial advice, investment advice, or a recommendation to buy or sell any security or options contract. This is not financial advice. Options trading involves risk, including earnings gaps, implied-volatility changes, assignment risk, spread widening, and the possible loss of the full premium paid. Review the site’s risk disclosure, earnings and implied-volatility guide, implied volatility explainer, options volume versus open interest guide, and risk-management primer. Options trading involves risk and is not suitable for all investors.
What Clorox has already confirmed
The confirmed facts heading into the event are straightforward.
- Clorox said it will issue fourth-quarter and fiscal-year 2026 results on Monday, August 3, 2026, at 4:15 p.m. ET, followed by a 5:00 p.m. ET webcast.
- In fiscal Q3 2026, Clorox reported net sales of USD 1.67 billion, flat versus the year-ago quarter.
- Organic sales in fiscal Q3 2026 decreased 1%.
- Gross margin in fiscal Q3 2026 was 43.2%, down 140 basis points from the prior-year quarter.
- Diluted EPS in fiscal Q3 2026 was USD 1.54, while adjusted EPS was USD 1.64.
- Management’s fiscal-year 2026 outlook after the Q3 release called for net sales down about 6%, organic sales down about 9%, diluted EPS of USD 4.78 to USD 4.98, and adjusted EPS of USD 5.45 to USD 5.65.
- Clorox said the reversal of incremental shipments made ahead of its ERP transition was expected to reduce fiscal-year sales growth by about 7.5 points and EPS by about USD 0.90.
- On June 17, 2026, the company announced a simplified operating structure intended to improve execution and accelerate growth.
- On April 1, 2026, Clorox completed its acquisition of GOJO Industries, bringing the Purell brand into the portfolio.
Those details matter because they define the event before any options chain is discussed. Clorox has already told the market that the business is working through an awkward mix of flat headline sales, ERP-related shipment reversal, cost pressure, portfolio change, and an operating-structure reset. That tends to make the post-earnings reaction less about whether a staples company should be stable in theory and more about whether management can prove the instability is temporary in practice.
Why This Matters For Options Traders
Clorox’s August 3 report matters for options traders because it sits at the intersection of several debates that can all move a lower-beta stock at once. The market has to decide how much of the weak fiscal-year 2026 framing should be treated as timing noise from the ERP transition, how much is true category-demand softness, and how much comes from margin pressure and execution friction.
That matters for options because a staples stock does not need a dramatic headline shock to reprice. It may only need management to sound less confident about volume normalization, more cautious on gross-margin recovery, or less convincing on the idea that ERP-related disruption is mostly behind it. A lower-volatility label does not prevent a quick reset when expectations are already divided.
It also matters because Clorox is entering the event with more than one storyline attached to the same print. Traders will hear about category trends, margins, inventory normalization, operating simplification, and the effect of the GOJO acquisition in the same update. Near-dated premium can therefore reflect uncertainty about interpretation, not just uncertainty about the top-line or EPS number.
Why this is an options event, not just a staples earnings date
Clorox is useful for options readers because several practical questions converge at the same time.
First, management has already lowered the fiscal-year frame. After Q3, Clorox guided to lower full-year sales and earnings while explicitly pointing to the reversal of pre-ERP shipments as a meaningful drag. When the company has already pre-explained part of the weakness, the August 3 reaction may depend less on the absolute numbers and more on whether investors believe the clean-up phase is nearing an end.
Second, the margin picture is still under pressure. Gross margin in Q3 was 43.2%, down 140 basis points year over year, even with cost savings helping adjusted EPS. That creates a real setup question for options traders: is the company close to rebuilding margin quality, or is the margin repair still too fragile to support a calm defensive multiple?
Third, the company is changing structure while integrating a large acquisition. The simplified operating structure announced in June and the completed GOJO transaction both matter because they give management more ways to explain future improvement, but they also give the market more moving parts to judge. For options traders, that matters because complex restructuring stories can still produce a meaningful post-earnings move even when the business is not high beta.
The main things CLX options traders should actually watch
1. Whether management still treats the ERP drag as transitory
The cleanest pre-event question is whether the company continues to frame fiscal 2026 weakness as mostly an unwind of earlier ERP-related shipment timing. Clorox has already said the reversal of incremental shipments is expected to reduce fiscal-year sales growth by about 7.5 points and EPS by about USD 0.90.
That matters because the market can tolerate temporary distortion more easily than structural weakness. If management sounds confident that the ERP unwind is largely a timing issue that is fading, traders may view the print as a normalization checkpoint. If the company adds new caveats, investors may decide the disruption is lasting longer than expected.
2. Whether gross-margin recovery is becoming credible
Q3 gross margin fell to 43.2% from 44.6% a year earlier. Clorox said higher manufacturing and logistics costs plus unfavorable mix were the main pressures, partially offset by cost savings.
For options traders, that means August 3 is not just about revenue. It is also about whether margin recovery is becoming more believable. A staples company can look optically cheap or stable, but if the margin base is still unsettled, the stock can still reprice when guidance tone shifts.
3. Whether volume normalization is broad or still uneven
Clorox’s Q3 release described flat net sales and a 1% decline in organic sales, which means the company is not yet showing a clean broad-based acceleration. That matters because the market still needs to separate category stabilization from one-off shipment timing and acquisition noise.
If management points to broader consumption improvement across categories, traders may treat the event as a cleaner turn story. If recovery remains patchy, the market may continue to value Clorox more like a slow repair case than a stable staples compounder.
4. Whether restructuring language becomes a substitute for operating proof
The June 17 simplified operating-structure announcement matters, but it does not settle the August 3 earnings debate on its own. Reorganizations can improve accountability and execution over time, but they do not automatically translate into immediate demand or margin improvement.
That does not make the restructuring irrelevant. It makes the interpretation narrower. Options traders should focus on whether management can tie the new structure to measurable operating progress rather than assuming any reorganization headline is automatically bullish.
5. Whether traders confuse “defensive” with “low event risk”
This is one of the most common mistakes in staples names. Clorox may trade with lower beta than many technology or small-cap earnings names, but that does not mean event risk disappears. When sales, margins, execution, and guidance are all in question at once, even a defensive stock can produce a meaningful one-day repricing.
What traders may misunderstand
A staples label means the options event should be small
It does not. Lower-beta names can still gap when the market is uncertain about margins, volume quality, and management credibility. The sector label alone does not settle the event.
Lower guidance already removed the risk
Not necessarily. Pre-explained weakness can reduce surprise on one axis while increasing scrutiny on another. If the market thinks the reset should have cleaned up expectations, a print that still feels messy can disappoint anyway.
ERP timing noise means the operating trend does not matter
Wrong frame. Timing effects matter, but they do not erase the need to judge consumption, mix, and margin quality. Traders still have to decide whether the company is emerging from the disruption with a stronger core business or simply with a cleaner excuse.
Management commentary on simplification guarantees improvement
No. Structural changes can help over time, but the August 3 event still matters because investors will want evidence that the reorganization is improving execution rather than only changing the org chart.
Options premium reveals direction
No. Options pricing can reflect hedging demand, event uncertainty, and differing interpretations of the same facts. It can show that the market expects a meaningful information event. It does not show which direction the stock must move after earnings.
Bottom line
Clorox’s August 3, 2026 earnings date matters because the company has already framed fiscal 2026 as a messy transition year. Q3 net sales were USD 1.67 billion, organic sales fell 1%, gross margin slipped to 43.2%, and management lowered the full-year outlook while saying ERP-related shipment reversal was a major drag.
That gives options traders a cleaner job than simply asking whether a staples company will beat or miss. Watch whether management still sounds confident that the ERP unwind is transitory, whether margin recovery is becoming more believable, and whether volume normalization is broad enough to support a calmer multiple again. Then compare the realized stock reaction with the uncertainty that had been priced into the event before the numbers arrived. That is options education and market context, not financial advice.
Sources
- The Clorox Company Investor Relations, “Clorox Announces August 3 Webcast of Fourth-Quarter and Fiscal Year 2026 Results” (plain-text URL):
https://investors.thecloroxcompany.com/news/news-details/2026/Clorox-Announces-August-3-Webcast-of-Fourth-Quarter-and-Fiscal-Year-2026-Results/default.aspx - The Clorox Company Investor Relations, “Clorox Reports Q3 Fiscal Year 2026 Results, Updates Outlook” (plain-text URL):
https://investors.thecloroxcompany.com/news/news-details/2026/Clorox-Reports-Q3-Fiscal-Year-2026-Results-Updates-Outlook/default.aspx - The Clorox Company Investor Relations, “Clorox Announces Simplified Operating Structure to Improve Execution and Accelerate Growth” (plain-text URL):
https://investors.thecloroxcompany.com/news/news-details/2026/Clorox-Announces-Simplified-Operating-Structure-to-Improve-Execution-and-Accelerate-Growth/default.aspx - The Clorox Company Investor Relations, “Clorox Completes Acquisition of GOJO Industries, Makers of Purell” (plain-text URL):
https://investors.thecloroxcompany.com/news/news-details/2026/Clorox-Completes-Acquisition-of-GOJO-Industries-Makers-of-Purell/default.aspx
